Vor Bio reports engraftment data from 5 AML patients in trem-cel study; FDA clears VCAR33 ALLO IND

Vor Biopharma Inc.

All 5 trem-cel patients achieved neutrophil engraftment in 10-11 days; high myeloid donor chimerism at day 28.
Patient 2 had secondary graft failure coincident with coronavirus hKU1 and antimicrobials; backup graft restored engraftment.
Patient 3 has recovering platelets with autoimmune thrombocytopenia; count 15,000/µL independent of transfusions.
Patients 4 and 5 had normal engraftment and recovery with no unexpected adverse events; cell doses met release criteria.
FDA cleared IND for VCAR33 ALLO (allogeneic CAR-T targeting CD33); VBP301 trial to focus on relapsed post-allo-SCT patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.